All conditions

Psoriatic Arthritis

Plain English clinical trial information, updated daily from ClinicalTrials.gov and public government registries. Not medical advice.

476
Trials on record
77
Recruiting now
6
Australian sites
12
Phase 3 trials
14
PBS medicines
How these figures are counted
  • Trials on record is every trial tagged to this condition at any stage, except those withdrawn before starting or terminated early. Most are completed rather than ongoing, so this is a measure of research history, not of current activity. It is also smaller than the sitewide "trials tracked" figure, which does include withdrawn and terminated trials.
  • Recruiting now counts only trials whose registry status is "Recruiting". Trials listed as not yet recruiting or enrolling by invitation are excluded, so this understates how many may open to new participants soon.
  • Australian sites counts trials counted under "Recruiting now" that list at least one Australian site. A site being listed does not mean it is currently enrolling, and Australian trials registered only on ANZCTR are not counted yet, so this understates local availability.
  • Phase 3 trials counts trials counted under "Recruiting now" that are at Phase 3.

Find recruiting trials for Psoriatic Arthritis →

Get alerts when Psoriatic Arthritis trials change ↗

Voxsanity currently covers 103 conditions. We are expanding coverage regularly.

Understanding Psoriatic Arthritis

Psoriatic arthritis is a condition where the immune system mistakenly attacks the body's own joints and skin, causing inflammation. This inflammation can lead to joint pain, stiffness, and swelling, as well as the red, scaly skin patches associated with psoriasis. The two conditions often appear together, though some people develop joint symptoms before any skin changes are noticed. Psoriatic arthritis can affect different parts of the body, including the fingers, toes, spine, and the places where tendons and ligaments attach to bone.

In Australia, psoriatic arthritis is relatively common, affecting an estimated 2–3% of people who have psoriasis, though the condition can also occur without a significant skin history. It can develop in adults of any age, though it most often appears between the ages of 30 and 50, and it affects men and women at roughly similar rates. Arthritis Australia estimates that around 23,000 Australians live with psoriatic arthritis, and because it can sometimes be mistaken for other forms of arthritis, it may take some time to reach a confirmed diagnosis.

Treatment in Australia is generally managed by a rheumatologist, often working alongside a dermatologist if skin involvement is significant. The overall aim of treatment is to reduce inflammation, relieve symptoms, and limit long-term joint damage. Depending on the severity of the condition, doctors may discuss options ranging from anti-inflammatory medications and disease-modifying drugs through to newer targeted therapies, some of which are available on the Pharmaceutical Benefits Scheme. Regular check-ins with a healthcare team help monitor how the condition is responding over time.

This overview is an AI generated summary written from public medical sources and checked on a sample basis. It is general information, not medical advice or a diagnosis. Always speak with your doctor about your situation. How we use AI

Can you access treatment for Psoriatic Arthritis in Australia right now? Here's what's publicly known.

Information on this site does not constitute medical advice. Data is sourced from publicly available government registries. Always consult your doctor before making any health decisions. Trial status should be verified directly with the trial site.

Updated regularly from public government registries

PBS-subsidised medicines for Psoriatic Arthritis

14 medicines listed on the PBS for Psoriatic Arthritis. Filter by authority type, or open the full table below.

What the authority types mean Unrestricted: no clinical criteria; a doctor can prescribe it on the PBS for any appropriate use. Restricted benefit: subsidised only for the specific conditions or uses set out by the PBS. Streamlined authority: restricted, but the doctor does not need prior approval; they record a streamlined authority code confirming you meet the criteria. Authority required: restricted, and the doctor must get prior approval from Services Australia (by phone or online) before it is subsidised. Source: Pharmaceutical Benefits Scheme (pbs.gov.au).
Full PBS medicines table 14 listed

These medicines are listed on the Pharmaceutical Benefits Scheme (PBS) for the specific indications shown. A listing does not mean a medicine is right for you; your doctor decides what is appropriate. Prices shown are the PBS-determined dispensed price. Most patients pay only the standard co-payment, up to AU$25.00 per script (general) or AU$7.70 (concession or Safety Net) in 2026, with the Australian Government subsidising the rest.

Medicine Brand(s) Listed for
Adalimumab Hyrimoz, Hadlima, Yuflyma +1 more psoriatic arthritis Severe AU$444.17 Authority required
bimekizumab Bimzelx psoriatic arthritis Severe AU$3260 Authority required
Certolizumab pegol Cimzia psoriatic arthritis Severe AU$938.04 Authority required
Etanercept Enbrel, Brenzys psoriatic arthritis Severe AU$371.81 Authority required
Golimumab Simponi psoriatic arthritis Severe AU$939.99 Authority required
Guselkumab Tremfya psoriatic arthritis Severe AU$3452.89 Authority required
Infliximab Remsima SC, Inflectra psoriatic arthritis Severe AU$186.16 Authority required
Ixekizumab Taltz psoriatic arthritis Severe AU$3097 Authority required
Risankizumab Skyrizi psoriatic arthritis Severe AU$4977.33 Authority required
Secukinumab Cosentyx psoriatic arthritis Severe AU$625.37 Authority required
Tofacitinib Xeljanz psoriatic arthritis Severe AU$1037.85 Authority required
Upadacitinib Rinvoq psoriatic arthritis Severe AU$1092.47 Authority required
Ustekinumab Wezlana, Steqeyma psoriatic arthritis Severe AU$716.69 Authority required
Leflunomide Arava active psoriatic arthritis Severe AU$10.15 Restricted benefit

Source: Pharmaceutical Benefits Scheme (PBS), © Commonwealth of Australia. Data used and redistributed under permission; not modified from its original wording where displayed verbatim.

Research pipeline

Where trials for Psoriatic Arthritis currently sit in the development pipeline. The funnel shape shows how few drugs reach later phases in general; the counts are this condition's actual trial numbers.

Phase success rates are industry-wide historical averages, not predictions for specific trials. Learn how trials work →

Most active research sponsors

Organisations with the most recruiting trials for Psoriatic Arthritis.

View sponsor profile
View sponsor profile
View sponsor profile
View sponsor profile
View sponsor profile

Where trials are running

Clinical trial sites for Psoriatic Arthritis by country. Australia is highlighted.

Showing the top 10 of 58 countries with trial sites.

Clinical trials for Psoriatic Arthritis

Showing 83 of 83 trials

The plain English eligibility text on each trial below is an AI generated summary of the official criteria, checked on a sample basis. How we use AI

🇦🇺 NCT03675308 · AbbVie Phase 3 · 39 countries Active, Not Recruiting
Active, Not Recruiting Phase 3 Est. completion 8 October 2020
🇦🇷 AR🇦🇺 AU🇧🇪 BE Bosnia and Herzegovina🇧🇷 BR🇧🇬 BG🇨🇦 CA🇨🇱 CL +31 more

**Who might be able to join this trial:** - You have been diagnosed with Psoriatic Arthritis (PsA) with symptoms that started at least 6 months before your screening appointment, and you meet the standard classification criteria for PsA. - You have active disease at the start of the trial, meaning at least 5 joints tha...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT01392326 · Novartis Pharmaceuticals Phase 3 · 19 countries Completed
Completed Phase 3 Est. completion 1 October 2014
🇦🇷 AR🇦🇺 AU🇧🇪 BE🇧🇷 BR🇧🇬 BG🇨🇦 CA🇨🇿 CZ🇩🇪 DE +11 more

**Who might be able to join this trial:** - You are male, or a female who is not pregnant and not breastfeeding, and you are at least 18 years old - You have been diagnosed with Psoriatic Arthritis (PsA) using a specific set of medical criteria called CASPAR, your symptoms have been present for at least 6 months, and y...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT01690299 · Amgen Phase 3 · 11 countries Completed
Completed Phase 3 Est. completion 3 July 2014
🇦🇺 AU🇧🇪 BE🇨🇦 CA🇨🇿 CZ🇪🇪 EE🇩🇪 DE🇭🇺 HU🇱🇻 LV +3 more

**Who might be able to join this trial:** - You are 18 years of age or older - You have been diagnosed with moderate to severe plaque psoriasis for at least 12 months before screening, and you are a suitable candidate for light therapy or systemic (whole-body) treatments - You have previously tried at least one standar...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT02814175 · AbbVie Phase 4 · 14 countries Completed
Completed Phase 4 Est. completion 23 September 2019
🇦🇺 AU🇧🇷 BR🇧🇬 BG🇨🇦 CA🇨🇴 CO🇨🇿 CZ🇩🇪 DE🇮🇹 IT +6 more

Who might be able to join this trial: - You have been diagnosed with Psoriatic Arthritis (a condition causing joint pain and skin symptoms) for at least 4 weeks before your screening appointment, confirmed using a standard set of medical criteria. - Your Psoriatic Arthritis is not currently well-controlled or in a low-...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
🇦🇺 NCT03773965 · Eli Lilly and Company Phase 3 · 20 countries Recruiting
Recruiting Phase 3 Est. completion 1 July 2031
🇦🇷 AR🇦🇺 AU🇦🇹 AT🇧🇪 BE🇧🇷 BR🇨🇳 CN🇨🇿 CZ🇩🇰 DK +12 more

**Who might be able to join this trial:** - People who have already completed a previous clinical study of baricitinib as a treatment for juvenile idiopathic arthritis (a type of arthritis that affects children and young people). **Who may not be able to join:** - People who permanently stopped taking baricitinib duri...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT06100744 · AbbVie Phase 3 · 9 countries Recruiting
Recruiting Phase 3 Est. completion 1 September 2026
🇦🇺 AU🇨🇦 CA🇫🇷 FR🇩🇪 DE🇮🇹 IT🇵🇱 PL🇪🇸 ES🇬🇧 GB +1 more

Who might be able to join this trial: - People who have been diagnosed with juvenile psoriatic arthritis (a type of arthritis linked to psoriasis in children and young people) for at least 3 months before the screening visit, based on recognised international criteria. - People who have active arthritis in 3 or more jo...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT06663332 · Janssen Research & Development, LLC Phase 3 · 15 countries Recruiting
Recruiting Phase 3 Est. completion 12 December 2031
🇦🇷 AR🇦🇺 AU🇧🇷 BR🇨🇳 CN🇫🇷 FR🇩🇪 DE🇮🇹 IT🇯🇵 JP +7 more

**Who might be able to join this trial:** - You must have already completed all planned doses in the original pediatric guselkumab study. - The study doctor must believe that you are still benefiting from continuing guselkumab treatment. - If you are able to have children, you must either not be sexually active, be pra...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT06671496 · Takeda Phase 3 · 12 countries Recruiting
Recruiting Phase 3 Est. completion 18 May 2027
🇦🇷 AR🇦🇺 AU🇧🇷 BR🇨🇦 CA🇨🇳 CN🇫🇷 FR🇩🇪 DE🇯🇵 JP +4 more

**Who might be able to join this trial:** - You are 18 years old or older at the time of signing the consent form - You have been diagnosed with Psoriatic Arthritis (PsA) - You have had signs and symptoms of PsA for at least 3 months before the screening visit - You meet a specific set of recognised medical standards...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT06807424 · Janssen Research & Development, LLC Phase 3 · 24 countries Recruiting
Recruiting Phase 3 Est. completion 10 February 2027
🇦🇷 AR🇦🇺 AU🇧🇷 BR🇧🇬 BG🇨🇦 CA🇨🇳 CN🇨🇿 CZ🇩🇰 DK +16 more

**Who might be able to join this trial:** - People who have active psoriatic arthritis (PsA) that has not been fully controlled despite having tried at least one of the following: a non-biologic DMARD medication, apremilast, or one biologic medication - People who have had a confirmed diagnosis of PsA for at least 3 m...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT07455578 · Seismic Therapeutic AU Pty Ltd Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 September 2027
🇦🇺 AU

Who might be able to join this trial: **General requirements (all participants):** - Adults between 18 and 75 years old - Having a body weight of at least 45 kg (about 99 lbs) and a body mass index (a height-to-weight measure) between 18 and 40 - Using reliable contraception if able to become pregnant, or having a neg...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT04115748 · Gilead Sciences Phase 3 · 13 countries Terminated
Terminated Phase 3 Est. completion 19 January 2021
🇦🇺 AU🇧🇬 BG🇨🇦 CA🇨🇿 CZ🇭🇺 HU🇯🇵 JP🇳🇿 NZ🇵🇱 PL +5 more

**Who might be able to join this trial:** - You have been diagnosed with Psoriatic Arthritis (PsA) that meets specific medical classification standards, and you have had this condition for at least 6 months before the screening visit - You have active joint inflammation, meaning at least 3 swollen joints and at least...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07654751 · Janssen Research & Development, LLC Phase 4 · 1 country Not Yet Recruiting
Not Yet Recruiting Phase 4 Est. completion 31 August 2027
🇺🇸 US

**Who might be able to join this trial:** - You have been officially diagnosed with at least one condition that guselkumab is approved to treat — these include psoriasis, psoriatic arthritis, ulcerative colitis (UC), or Crohn's disease (CD) — as confirmed by your medical records - You are generally in a stable state o...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
NCT01581294 · Diakonhjemmet Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2050
🇳🇴 NO

Who might be able to join this trial: - You are older than 18 years of age - You have been diagnosed with rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, spondyloarthritis, juvenile idiopathic arthritis (diagnosed as an adult), undifferentiated arthritis, or any other type of inflammatory arthritis -...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT01848028 · Universitätsklinikum Hamburg-Eppendorf Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2032
🇩🇪 DE

Who might be able to join this trial: - People who have been diagnosed with plaque-type psoriasis or psoriatic arthritis by a skin specialist (dermatologist) - People who are 18 years of age or older - People who are starting a specific whole-body (systemic) medication for the first time - People who have given their a...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT01965132 · Seoul National University Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2029
🇰🇷 KR

**Who might be able to join this trial:** - You have been diagnosed with Rheumatoid Arthritis (RA), Ankylosing Spondylitis (AS), or Psoriatic Arthritis (PsA) - You have RA and your rheumatologist (joint specialist) has decided you need to start a biologic, targeted synthetic, or conventional DMARD (a type of medication...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT02103361 · University of California, San Diego Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 May 2030
🇺🇸 US

Who might be able to join this trial: - People who were exposed to Stelara (ustekinumab) or Tremfya (guselkumab) at any point during pregnancy, or within 3 months before the first day of their last menstrual period, regardless of how long they took it, the dose, or how many times. - People for whom there is a record of...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT02418442 · Duke University Not Applicable · 5 countries Recruiting
Recruiting Not Applicable Est. completion 1 June 2028
🇨🇦 CA🇮🇱 IL🇮🇹 IT Puerto Rico🇺🇸 US

"Who might be able to join this trial: - Your rheumatic disease (a condition affecting joints, muscles, or connective tissue) must have started before age 16 if you have Juvenile Idiopathic Arthritis (JIA), or before age 19 if you have a different rheumatic disease. - You (and/or your parent or legal guardian if needed...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT03248284 · Odense University Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2026
🇩🇰 DK

**Who might be able to join this trial:** - You have been diagnosed with Psoriatic Arthritis (PsA), confirmed using a standard set of medical criteria called the CASPAR criteria (confirm with trial site) - You have pain at the back of your heel where your Achilles tendon attaches to the bone - An ultrasound scan of you...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT03768271 · Assistance Publique - Hôpitaux de Paris Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2031
🇫🇷 FR

Who might be able to join this trial: - You are a woman or man between 18 and 65 years old (inclusive) - You have had your first episode of joint swelling or pain affecting limbs or peripheral joints within the last 12 months, confirmed by a rheumatologist (a joint specialist) - You have been diagnosed with psoriasis (...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04014413 · Chinese University of Hong Kong Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 October 2030
Hong Kong

**Who might be able to join this trial:** - You have been officially diagnosed with Crohn's disease - You have been officially diagnosed with ulcerative colitis - You have been officially diagnosed with celiac disease - You have been officially diagnosed with irritable bowel syndrome (IBS) - You have been officially d...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04191395 · Centre Hospitalier Universitaire de Besancon Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2029
🇫🇷 FR

**Who might be able to join this trial:** - People being treated for an inflammatory bowel disease (such as microscopic colitis, ulcerative colitis, or indeterminate colitis) in the gastroenterology department at Besançon University Hospital, and whose diagnosis meets specific clinical, imaging, and tissue-sample crit...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04504136 · Terrence A Barrett Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 June 2026
🇺🇸 US

Who might be able to join this trial: **Group 1 (Inflammatory Bowel Disease):** - People who have been diagnosed with ulcerative colitis or Crohn's disease - People who have either tried biologic treatments and they did not work, or who have never tried biologic treatments - People whose condition means a doctor consi...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04800289 · Centre Hospitalier le Mans Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 July 2030
🇫🇷 FR

"Who might be able to join this trial: - People who have attended a joint consultation involving both a rheumatologist (joint specialist) and a dermatologist (skin specialist) at Le Mans Hospital. Who may not be able to join: - People who have not been given a confirmed diagnosis of psoriatic arthritis (a condition in...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04804553 · Amgen Phase 3 · 15 countries Recruiting
Recruiting Phase 3 Est. completion 21 March 2028
🇦🇹 AT🇧🇪 BE🇫🇷 FR🇩🇪 DE🇬🇷 GR🇮🇹 IT🇱🇹 LT🇳🇱 NL +7 more

**Who might be able to join this trial:** - Children and teenagers aged 5 to under 18 years old at the time of joining the trial. - People who have been diagnosed with juvenile psoriatic arthritis (a type of childhood arthritis linked to the skin condition psoriasis) for at least 6 months, confirmed using specific int...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT04846959 · AbbVie Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 June 2032
🇺🇸 US

**Who might be able to join this trial:** *For the Risankizumab-Exposed Group:* - People who currently live in the United States - People who are currently pregnant - People who have been diagnosed with plaque psoriasis, psoriatic arthritis, Crohn's disease, or another condition for which the drug risankizumab is FDA-...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04876781 · Pfizer Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 22 September 2026
🇰🇷 KR

Who might be able to join this trial: - You are an adult (18 or older) taking Xeljanz® XR as prescribed for moderate to severe rheumatoid arthritis, and a previous treatment called methotrexate did not work well enough for you or you could not tolerate it - You are an adult (18 or older) taking Xeljanz® XR together wit...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04924270 · Odense University Hospital Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 March 2027
🇩🇰 DK

**Who might be able to join this trial:** - You have recently been diagnosed with one of the following conditions for the first time: rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis, Crohn's disease, or ulcerative colitis - You have not taken any medications to treat your condition (such as...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05291819 · Diakonhjemmet Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2027
🇳🇴 NO

**Who might be able to join this trial:** - You are over 18 years of age - You have been diagnosed with Psoriatic Arthritis (PsA) by a doctor - Your doctor has recommended you start a specific type of medication called a DMARD, and if your main symptoms are in your spine or tendons/ligament attachment points, you have...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05307809 · Poitiers University Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 17 August 2026
🇫🇷 FR

**Who might be able to join this trial:** **If you have psoriasis (skin condition only):** - You are 18 years of age or older - You are willing to sign a consent form agreeing to take part - You have had psoriasis for at least 5 years - You have at least one skin patch/lesion larger than 2 cm - You have no joint pain...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05652608 · Global Healthy Living Foundation Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 March 2026
🇺🇸 US

Who might be able to join this trial: - You must live in the United States or a U.S. territory - You must be at least 19 years old if you live in the U.S., or at least 21 years old if you live in Puerto Rico - You must have been told by a doctor that you have psoriatic arthritis (a condition that causes joint pain and...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05657847 · Semmelweis University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 February 2027
🇭🇺 HU

Who might be able to join this trial: - People who have been diagnosed with rheumatoid arthritis (based on EULAR/ACR criteria), psoriatic arthritis (based on CASPAR criteria), or crystal arthropathies (a type of joint disease caused by crystal deposits, such as gout) - People who have signed a form agreeing to take par...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05754710 · Pfizer Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 September 2026
🇰🇷 KR

**Who might be able to join this trial:** - Children and teenagers aged 2 years old up to (but not including) 18 years old - People whose doctor has decided to prescribe Xeljanz based on their medical judgement and in line with the approved prescribing guidelines - People for whom Xeljanz has been prescribed according...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05858528 · University of Oxford Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 June 2026
🇬🇧 GB

Who might be able to join this trial: - You are 18 years old or older - You have been told by a doctor that you have skin psoriasis (any type) - You are willing and able to give your consent to take part in the study and can complete study materials in one of the languages the study is available in (confirm with trial...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05954364 · Women's College Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 June 2026
🇨🇦 CA

Who might be able to join this trial: - People who have been diagnosed with Psoriatic Arthritis (PsA) by a specialist called a rheumatologist, confirmed using a standard set of medical criteria called CASPAR - People who are 18 years of age or older - People whose Psoriatic Arthritis is currently active, with signs fou...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06176508 · Hansoh BioMedical R&D Company Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 28 April 2026
🇨🇳 CN

Who might be able to join this trial: - Adults aged between 18 and 75 years, either male or female. - People who have been diagnosed with psoriatic arthritis for at least 6 months and who meet a specific set of recognised classification criteria for psoriatic arthritis at the screening visit. - People with active joint...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06259890 · Centre Hospitalier Universitaire de Besancon Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 November 2026
🇫🇷 FR

Who might be able to join this trial: - You have been diagnosed with axial spondyloarthritis (a type of inflammatory arthritis affecting the spine, either confirmed on X-ray or not yet visible on X-ray) or psoriatic arthritis (a type of arthritis linked to psoriasis). - If you are a woman, you are either post-menopausa...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06299917 · The Danish Center for Expertise in Rheumatology Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 September 2027
🇩🇰 DK

**Who might be able to join this trial:** - You are between 18 and 65 years old. - You have been diagnosed with rheumatoid arthritis (RA), psoriatic arthritis (PsA), or axial spondyloarthritis (axSpA) by a specialist in joint conditions. - You currently do paid work (full-time or part-time) or are studying. - You can r...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06339957 · University of Central Florida Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 July 2025
🇺🇸 US

Who might be able to join this trial: - You must be an adult aged 18 to 65 years old - You must already be a patient at UCF Health - You must have been diagnosed with one of the following conditions: rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, dermatomyositis/polymyositis, Sjögren's Syndrome, sys...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06382051 · Novartis Pharmaceuticals Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 28 August 2026
🇨🇦 CA

**Who might be able to join this trial:** - You have moderate-to-severe plaque psoriasis (a skin condition causing thick, scaly patches) and your doctor believes you are a good candidate for a type of advanced medication called a biologic - You are an adult at the time you sign the consent form to join the study - You...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06454188 · CARE ARTHRITIS LTD. Phase 4 · 2 countries Recruiting
Recruiting Phase 4 Est. completion 1 September 2028
🇨🇦 CA🇺🇸 US

**Who might be able to join this trial:** - People who are 18 years of age or older at the time of their screening visit. - People who are able to understand the study requirements and are willing to sign a consent form before any study procedures begin. - People who have been diagnosed with Psoriatic Arthritis (PsA)...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
NCT06498167 · Universidade do Porto Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 October 2024
🇵🇹 PT

Who might be able to join this trial: - You have been prescribed Rinvoq™ (upadacitinib) on or after January 1, 2024 - You are 18 years of age or older at the time of joining the study - You are willing to give your consent to take part in the study Who may not be able to join: - You have any level of cognitive difficu...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06533423 · Glostrup University Hospital, Copenhagen Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 May 2027
🇩🇰 DK

Who might be able to join this trial: - You are 18 years old or older - You have been diagnosed with Rheumatoid Arthritis (a condition where the immune system attacks the joints) within the last 6 months - You have been diagnosed with Psoriatic Arthritis (a joint condition linked to the skin condition psoriasis) within...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06583980 · The Danish Center for Expertise in Rheumatology Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 August 2027
🇩🇰 DK

**Who might be able to join this trial:** - You are 18 years of age or older - You have been diagnosed with rheumatoid arthritis (RA), psoriatic arthritis (PsA), or axial spondyloarthritis (axSpA) by a specialist for at least 2 years, and have been a patient at one of the participating hospital rheumatology departments...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06586281 · University of California, San Diego Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 September 2027
🇺🇸 US

**Who might be able to join this trial:** - You are an adult who has been diagnosed with Psoriatic Arthritis (PsA) using a recognised set of medical criteria called CASPAR - You have one or more swollen joints and/or one or more painful, tender spots where tendons or ligaments attach to bone (enthesitis) - You have one...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06628206 · LAPIX Therapeutics Inc. Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 15 December 2025
🇯🇴 JO

**Who might be able to join this trial:** - People who have signed a consent form before any study procedures begin. - People aged 18 or older, of any race or ethnicity. - People whose body weight falls within a healthy range for their height (BMI between 18.0 and 35.0). - People who are willing and able to attend sch...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06641089 · MoonLake Immunotherapeutics AG Phase 3 · 11 countries Recruiting
Recruiting Phase 3 Est. completion 15 January 2027
🇧🇬 BG🇨🇦 CA🇨🇿 CZ🇫🇷 FR🇬🇪 GE🇩🇪 DE🇭🇺 HU🇵🇱 PL +3 more

**Who might be able to join this trial:** - People aged 18 or older. - People who have been formally diagnosed with psoriatic arthritis (a condition causing joint inflammation linked to the skin condition psoriasis) according to a specific set of classification standards, and who have had symptoms for at least 6 month...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06666452 · The Danish Center for Expertise in Rheumatology Not Applicable · 2 countries Recruiting
Recruiting Not Applicable Est. completion 1 April 2026
🇩🇰 DK🇸🇪 SE

**Who might be able to join this trial:** - People who currently have a high level of fatigue, scoring 60 or above on a specific fatigue scale (a 0–100 scale) - People who have been experiencing fatigue as a significant problem for at least the past 3 months - People who have been diagnosed with Rheumatoid Arthritis,...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06668181 · UCB Biopharma SRL Phase 3 · 6 countries Recruiting
Recruiting Phase 3 Est. completion 12 April 2028
🇨🇦 CA🇫🇷 FR🇩🇪 DE🇵🇱 PL🇪🇸 ES🇬🇧 GB

**Who might be able to join this trial:** - You must be between 2 and 17 years old (inclusive) at the start of the study. - You must have been diagnosed with enthesitis-related arthritis (a type of arthritis affecting the places where tendons and ligaments attach to bone) and/or juvenile psoriatic arthritis (a type of...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06671483 · Takeda Phase 3 · 20 countries Recruiting
Recruiting Phase 3 Est. completion 18 May 2027
🇧🇪 BE🇧🇬 BG🇨🇱 CL🇭🇷 HR🇨🇿 CZ🇪🇪 EE🇩🇪 DE🇭🇺 HU +12 more

**Who might be able to join this trial:** - People who are 18 years of age or older at the time of signing the consent form (19 or older if in South Korea) - People who have been diagnosed with psoriatic arthritis (PsA) - People who have had signs and symptoms of psoriatic arthritis for at least 3 months before the sc...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06696027 · University of Bonn Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2025
🇩🇪 DE

"Who might be able to join this trial: - You are male. - You are over 50 years old. - You have been diagnosed by your doctor with one of the following conditions: a type of arthritis (such as rheumatoid arthritis or psoriatic arthritis), a connective tissue disease (such as lupus, systemic sclerosis, Sjögren's syndrome...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06718569 · Diakonhjemmet Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 November 2027
🇳🇴 NO

Who might be able to join this trial: - People who are starting or switching to a biological or targeted synthetic DMARD (a type of medicine used to treat certain immune system conditions, such as rheumatoid arthritis) Who may not be able to join: - There are no stated exclusion criteria for this trial — no groups of...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06730334 · Nanjing Medical University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 September 2026
🇨🇳 CN

Who might be able to join this trial: - You have been diagnosed with Psoriatic Arthritis (PsA) based on a specific set of medical guidelines called the CASPAR criteria. - You are able to attend all scheduled visits and follow the study plan, including any required tests and procedures. - You are willing and able to giv...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06751238 · Novartis Pharmaceuticals Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 30 November 2032
🇺🇸 US

**Who might be able to join this trial:** - A parent or legal guardian must provide written consent before any study activities begin, and the child must also give their agreement if old enough to do so under local law. - Children and teenagers aged 2 years old up to (but not including) 18 years old at the time of scr...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06764693 · AbbVie Not Applicable · 15 countries Recruiting
Recruiting Not Applicable Est. completion 1 January 2029
🇦🇷 AR🇦🇹 AT🇧🇪 BE🇧🇬 BG🇨🇿 CZ🇫🇷 FR🇩🇪 DE🇬🇷 GR +7 more

"Who might be able to join this trial: - You have been diagnosed with psoriatic arthritis (a condition causing joint pain and skin problems), with symptoms that started at least 6 months before your first screening appointment, and your disease is confirmed to be currently active. - You have tried at least one medicati...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06786936 · NHS Greater Glasgow and Clyde Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 28 February 2027
🇬🇧 GB

**Who might be able to join this trial:** - You are between 18 and 74 years old - You have been diagnosed with psoriasis or psoriatic arthritis by a skin or joint specialist - Your doctor has already decided, as part of your normal care, that you should start one of these medications: secukinumab, bimekizumab, or ixek...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06842316 · Centre Hospitalier Régional d'Orléans Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 9 April 2027
🇫🇷 FR

**Who might be able to join this trial:** - You are 18 years of age or older (male or female) - You have been diagnosed by a rheumatologist with one of the following conditions: rheumatoid arthritis, spondyloarthropathy (with or without inflammatory bowel disease), psoriatic arthritis (with or without active psoriasis...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06864026 · Eli Lilly and Company Phase 4 · 2 countries Recruiting
Recruiting Phase 4 Est. completion 1 November 2027
Puerto Rico🇺🇸 US

**Who might be able to join this trial:** - People who have been diagnosed with active psoriatic arthritis by a rheumatologist or other healthcare professional experienced in treating this condition. - People with a Body Mass Index (BMI) of 30 or above (classified as obese), or a BMI between 27 and below 30 (classifie...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
NCT06865105 · AbbVie Phase 2 · 6 countries Recruiting
Recruiting Phase 2 Est. completion 1 December 2027
🇨🇦 CA🇨🇿 CZ🇫🇷 FR🇭🇺 HU🇵🇱 PL🇺🇸 US

**Who might be able to join this trial:** - You are willing and able to follow all the procedures required by the study. - You have been formally diagnosed with Psoriatic Arthritis (PsA) for at least 6 months before the screening visit, and your diagnosis meets a specific set of classification standards checked at scre...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06869551 · Bristol-Myers Squibb Phase 3 · 11 countries Recruiting
Recruiting Phase 3 Est. completion 6 March 2030
🇧🇷 BR🇧🇬 BG🇨🇳 CN🇨🇿 CZ🇩🇪 DE🇮🇹 IT Puerto Rico🇷🇴 RO +3 more

Who might be able to join this trial: - People who have been diagnosed with Juvenile Psoriatic Arthritis (JPsA). - People who have at least three joints affected by arthritis. - People who have tried at least one medication for JPsA for three months or more, but the medication did not work well enough or caused problem...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06870500 · South Valley University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 March 2026
🇪🇬 EG

**Who might be able to join this trial:** - You are 18 years old or older. - You have been diagnosed with psoriasis by a doctor, and your condition is considered moderate to severe, meaning it affects more than 10% of your body surface area, with a skin severity score (called PASI) between 5 and 10, and you may or may...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06888193 · UCB Biopharma SRL Phase 1 · 5 countries Recruiting
Recruiting Phase 1 Est. completion 3 May 2027
🇨🇦 CA🇩🇪 DE🇪🇸 ES🇨🇭 CH🇺🇸 US

**Who might be able to join this trial:** - You must be at least 18 years old at the time you sign the consent form to join the study. - You must currently be taking bimekizumab as prescribed by your doctor, following the approved guidelines for your area. - You must currently be breastfeeding and plan to continue brea...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07086599 · Fondation Hôpital Saint-Joseph Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 13 May 2027
🇫🇷 FR

Who might be able to join this trial: - People who are 18 years of age or older - People who have been diagnosed with psoriatic arthritis or SAPHO syndrome and are being treated at Paris Saint-Joseph Hospital - People who are experiencing sleep problems serious enough to require a hospital stay for further investigatio...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07086924 · South Valley University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 June 2026
🇪🇬 EG

**Who might be able to join this trial:** - You are between 18 and 70 years old - You have been diagnosed with plaque psoriasis (a common form of psoriasis affecting the skin) or psoriatic arthritis (a joint condition linked to psoriasis), confirmed by a skin or joint specialist - Your psoriasis has been measured as mo...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07087912 · University of Sao Paulo General Hospital Phase 4 · 1 country Recruiting
Recruiting Phase 4 Est. completion 30 December 2027
🇧🇷 BR

**Who might be able to join this trial:** - You are between 12 and 59 years old - You are male or female - You have been diagnosed with an autoimmune rheumatic disease (such as rheumatoid arthritis, lupus, juvenile idiopathic arthritis, Sjögren's syndrome, or vasculitis) based on recognised medical standards - Your aut...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
NCT07128472 · South Valley University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 20 January 2026
🇪🇬 EG

**Who might be able to join this trial:** - People who have been clinically diagnosed with psoriasis for at least 6 months, with a severity score greater than 10 on a standard psoriasis measurement scale, skin involvement covering more than 10% of the body surface, and who also have psoriatic arthritis (joint inflammat...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07141004 · Johnson & Johnson Private Limited Phase 4 · 1 country Recruiting
Recruiting Phase 4 Est. completion 5 June 2027
🇮🇳 IN

**Who might be able to join this trial:** - You have been formally diagnosed with active psoriatic arthritis (a type of arthritis linked to psoriasis), confirmed using a standard medical checklist, and your arthritis affects at least one specific pattern of joints in your body. - A blood test has shown you do not have...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
NCT07149792 · Taichung Veterans General Hospital Phase 4 · 1 country Recruiting
Recruiting Phase 4 Est. completion 31 December 2026
🇹🇼 TW

Who might be able to join this trial: - You are generally in good health (healthy volunteer) - You have been diagnosed with psoriasis (a skin condition) - You have been diagnosed with psoriatic arthritis (a joint condition linked to psoriasis) - You are willing to provide a blood sample Who may not be able to join: -...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
NCT07150000 · University of Bonn Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2028
🇩🇪 DE

Who might be able to join this trial: - You are 18 years old or older - You are willing to take part and able to sign a consent form agreeing to join the study - A doctor has confirmed you have one of the following conditions: rheumatoid arthritis, psoriatic arthritis, axial spondyloarthritis (a type of spinal inflamma...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07160231 · Sint Maartenskliniek Phase 4 · 1 country Recruiting
Recruiting Phase 4 Est. completion 1 May 2028
🇳🇱 NL

Who might be able to join this trial: - You are 16 years of age or older - You have been diagnosed with rheumatoid arthritis (RA), psoriatic arthritis (PsA), or axial spondyloarthritis (axSpA) - You are currently taking a type of medication called a JAK inhibitor (either alone or combined with another arthritis medicin...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
NCT07166315 · Adelphi Real World Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 March 2027
🇬🇧 GB

Who might be able to join this trial: - People who have been diagnosed with axial spondyloarthritis (a type of inflammatory arthritis affecting the spine) or psoriatic arthritis (a type of arthritis linked to psoriasis) - People whose doctor has prescribed an advanced therapy medication for one of these conditions with...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07180537 · Terry L. Wahls Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2027
🇺🇸 US

**Who might be able to join this trial:** - You have been diagnosed with one of the following conditions by a doctor: Rheumatoid Arthritis (RA), Sjögren's Syndrome, Lupus (SLE), Mixed Connective Tissue Disease (MCTD), or Psoriatic Arthritis (PsA). - You are 18 years of age or older at the time you agree to join the st...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07220824 · Janssen Research & Development, LLC Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 July 2027
🇮🇹 IT

**Who might be able to join this trial:** - You have been diagnosed with Psoriatic Arthritis (PsA) for at least 6 months, and your arthritis is currently active, meaning you have a minimum number of tender or swollen joints, or a blood test shows signs of inflammation - An ultrasound scan of your joints shows a certai...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07286058 · Takeda Phase 3 · 3 countries Recruiting
Recruiting Phase 3 Est. completion 18 December 2029
🇯🇵 JP Puerto Rico🇺🇸 US

**Who might be able to join this trial:** - People who are 18 years of age or older at the time of signing the consent form (in South Korea, this requirement is 19 years or older) - People who completed the full 52-week treatment period in one of the two related earlier studies (TAK-279-PsA-3001 or TAK-279-PsA-3002), r...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07290036 · UCB Biopharma SRL Phase 1 · 6 countries Recruiting
Recruiting Phase 1 Est. completion 18 May 2028
🇧🇬 BG🇨🇿 CZ🇩🇪 DE🇵🇱 PL🇸🇰 SK🇺🇸 US

**Who might be able to join this trial:** - You are 18 years old or older and able to give your own consent to participate - You have been diagnosed with active psoriatic arthritis or axial spondyloarthritis (a type of inflammatory spinal condition), and your doctor considers the study drug bimekizumab an appropriate t...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07295509 · Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD. Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 31 December 2029
🇨🇳 CN

Who might be able to join this trial: - People aged between 18 and 75 years - People who have been diagnosed with Psoriatic Arthritis (PsA) for at least 3 months, and who meet a standard set of classification criteria for PsA at the screening visit - People with currently active PsA, meaning at least 3 tender joints an...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07298265 · Charite University, Berlin, Germany Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 October 2026
🇨🇦 CA

Who might be able to join this trial: - You are 18 years old or older. - You have been officially diagnosed with psoriasis. - You are willing and able to sign a written consent form agreeing to take part in the trial. Who may not be able to join: - You are unable or unwilling to give your consent to participate, or yo...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07315061 · InventisBio Co., Ltd Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 15 August 2027
🇨🇳 CN

Who might be able to join this trial: - People who are willing to take part voluntarily, have been fully informed about the study, and agree to follow the study procedures by signing a consent form - People who are male or female, aged between 18 and 70 years old at the time of signing the consent form - People who hav...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07321873 · Janssen Research & Development, LLC Phase 2 · 8 countries Recruiting
Recruiting Phase 2 Est. completion 28 June 2027
🇨🇳 CN🇨🇿 CZ🇩🇪 DE🇭🇺 HU🇯🇵 JP🇵🇱 PL🇪🇸 ES🇺🇸 US

**Who might be able to join this trial:** - People who have been diagnosed with psoriatic arthritis (PsA) for at least 3 months before the study starts, and who meet a standard set of classification criteria for PsA at the screening visit - People with active PsA, meaning at least 3 swollen joints and at least 3 tende...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07443956 · NHS Greater Glasgow and Clyde Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 February 2028
🇬🇧 GB

**Who might be able to join this trial:** - People aged 18 to 75 years old - People who have had a confirmed diagnosis of Psoriatic Arthritis (PsA) for at least 6 months, and whose condition meets a specific set of classification criteria used by doctors (called the CASPAR criteria) - People whose PsA is currently act...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07486960 · Merck Sharp & Dohme LLC Phase 2 · 8 countries Recruiting
Recruiting Phase 2 Est. completion 13 August 2027
🇨🇦 CA🇨🇱 CL🇨🇴 CO🇩🇪 DE🇵🇱 PL🇪🇸 ES🇺🇦 UA🇺🇸 US

Who might be able to join this trial: - People who have been formally diagnosed with Psoriatic Arthritis (PsA) and meet a specific set of classification criteria for that condition, with symptoms that started at least 6 months before the screening visit. - People who have active plaque psoriasis (a skin condition causi...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07611747 · Instituto de Investigación Marqués de Valdecilla Phase 4 · 1 country Recruiting
Recruiting Phase 4 Est. completion 22 April 2031
🇪🇸 ES

**Who might be able to join this trial:** - You are 50 years old or older and are willing to sign a consent form agreeing to take part - You have been diagnosed with at least one of the following conditions: Rheumatoid Arthritis, Psoriatic Arthritis, Axial Spondyloarthritis, or Systemic Lupus Erythematosus, confirmed u...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
NCT07653009 · Marmara University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 2 June 2027
Turkey (Türkiye)

**Who might be able to join this trial:** - People who have been diagnosed with psoriatic arthritis using a specific set of medical criteria called the CASPAR criteria - People who are between 18 and 65 years old - People whose current treatment plan has remained unchanged for at least 12 weeks before joining the tria...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07718815 · Centre Hospitalier Universitaire, Amiens Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 September 2026
🇫🇷 FR

**Who might be able to join this trial:** **For the "Patient" group:** - People who are over 18 years of age - People who are affiliated with a social security scheme - People who have been diagnosed with psoriatic arthritis according to the CASPAR 2006 classification and are being followed at the CHU Amiens-Picardie...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Advocacy and support in Australia

Organisations that can offer information, support, or connection for Psoriatic Arthritis. Where more than one is listed, they serve different needs or regions, so choose whichever fits your situation.

Arthritis Australia is the national body for psoriatic arthritis and the other forms of arthritis it covers.

This is a starting point, not medical advice or an endorsement. Contact details change; search the organisation name to find its current website.